DRG Epidemiology's coverage of the RSV vaccine comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the prevalence of the RSV vaccine for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's RSV vaccine forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of the RSV vaccine over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following RSV vaccine patient populations:
Vaccine eligible population Newly eligible for vaccine population Note: coverage may vary by country and region.
RSV Vaccine-Eligible Population per 1,000 Children in 2021 and 2041
RSV Vaccine-Eligible Population per 1,000 Adults in 2021 and 2041
RSV Maternal-Vaccine-Eligible Population per 1,000 Women in 2021 and 2041
Analysis of the Total RSV Vaccine Eligible Population by Newly Eligible Status
Epidemiology Data
Methods
RSV Vaccine Eligible Population
Reference Materials
Literature Review
Studies Included in the Analysis of the RSV Vaccine Eligible Population
Studies Excluded from the Analysis of the RSV Vaccine Eligible Population
Risk/Protective Factors
Risk/Protective Factors for the RSV Vaccine Eligible Population
Bibliography
Abbreviations table
Glossary
Jagriti Prasad
Jagriti Prasad, M.P.H.,is an associate epidemiologist at Clarivate. Previously, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University (U.K.) and her B.D.S. from Manipal University (India).
Mudasir Khan, M.P.H.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
